Juvenile idiopathic arthritis (JIA) and pediatric joint disorders
Suzette Peng, MD
FDA
Potomac, MD, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Juwaria Waheed, MD
Food and Drug Administration
Silver Spring, MD, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
This session will review the latest pediatric rheumatology medication developments, including new agents, top adverse effects to be aware of, and any expanded disease applications for existing medications. We will discuss the growing list of biosimilar drugs available and review the current path from pediatric drug trial to Food and Drug Administration drug approval.
Speaker: Suzette Peng, MD – FDA
Speaker: Juwaria Waheed, MD – Food and Drug Administration
